Latest Breaking News On - Brian rodenhausen - Page 1 : comparemela.com

03.09.21 Incorporating Excipients Into QbD Studies For Drug Development An Introduction     Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs.   Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more!     By Brian Carlin (DFE Pharma), Chris Moreton (FinnBrit Consulting), Dave Schoneker (Black Diamond Consulting), Katherine Ulman (KLU Consulting), and Joseph Zeleznik (IMCD) This article is the first in a three-part series based on information from the new guide, “Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design,” published by the International Pharmaceutical Excipients Council Federation. Topics covered include measuring the impact of excipient variabili

Jens christoph matuszczykPim hermansElina klijsAlex armengolKevin sleijpenJames faustAnja overweelMelisa carpioRobert smithGerhard grellerFrank detmersJanice abelBrian rodenhausenSebastian ruhlAndy gollJens rupprecht